



*Making dementia a priority:
changing perceptions, practice and policy.*

CLINICAL TRIALS WATCH

ACCESSIBLE EASY READ INFORMATION ON:

TRAVELLER STUDY

TRAVELLER study

1. Study Information	
Name of the study	Master screening study to determine individuals with potential trial eligibility for Alzheimer's disease studies
Study sponsor	Hoffmann-La Roche
Disease	Objective or subjective memory concerns
Phase	Phase III
2. Information about participating in the trial	
What are the researchers trying to find out?	<ul style="list-style-type: none">• No drug or intervention is tested in this study. This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies, as assessed by cognitive and biomarker status.
What your involvement will entail?	<ul style="list-style-type: none">• At day 1, participants will undergo a blood test (to assess their concentration of pTau217 in blood) and the International Shopping List Test (ISLT) to evaluate cognitive function. <p>Further information can be obtained from the study team.</p>
3. Who can participate in this study?	
Who can participate in the study?	To take part in the study, participants must: <ul style="list-style-type: none">• Be between 50 and 90 years old• Have memory concerns within the last year with or without a previous clinical diagnosis of Mild Cognitive Impairment (MCI) or dementia due to Alzheimer's disease.
Who cannot participate in the study?	Exclusion criteria include: <ul style="list-style-type: none">• Dependency in basic activities of daily living due to cognitive impairment• Visual or auditory impairment that would prevent performing the cognitive assessments (eyeglasses and hearing aids

	<p>are permitted)</p> <ul style="list-style-type: none"> • Neurological or neurodegenerative condition that may lead to cognitive impairment other than Alzheimer's disease • History of severe, clinically significant central nervous system trauma • A disease that may interfere with the safety or study assessments. <p>The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study.</p>
--	--

4. Where and when will the study be conducted?

European countries involved in the study	<ul style="list-style-type: none"> • Denmark • Italy • Poland • Spain • UK
Estimated start date of recruitment	July 2025

5. Information for your doctor

Clinicaltrials.gov identifier	NCT07177352
Study contact information	global-roche-genentech-trials@gene.com
Link to full text	https://clinicaltrials.gov/study/NCT07177352
Study's website	https://forpatients.roche.com/en/trials/neurodegenerative-disorder/ad/screening-study-to-determine-individuals-with-potential-76396.html

- ✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov website) in September 2025.
- ✓ This document has been reviewed by the pharmaceutical company running this trial.